Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Alan Meds vs LillyDirect Foundayo

Alan Meds
Graded #99

Higher grade

vs+3.8999999999999915
LillyDirect Foundayo
Graded #173

Lower grade

The verdict

Alan Meds takes it — 71.1/100 to 67.2/100.

Alan Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth platform offering compounded semaglutide and tirzepatide with multiple administration formats including microdosing and oral options.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
72
72
Dose & formulationAlan Meds +16
75
59
Clinical oversightAlan Meds +4
82
78
Labs & monitoringAlan Meds +1
53
52
FulfillmentLillyDirect Foundayo +2
78
80
Contract termsEven
55
55
Alan Meds · left barLillyDirect Foundayo · right bar

The numbers

MetricAlan MedsLillyDirect Foundayo
WeighScore71.1/10067.2/100
GradeCC
Scorecard rank#99#173
Semaglutide$158/mo (compounded)Not disclosed
Tirzepatide$295/mo (compounded)Not disclosed
Coverage46 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Alan Meds

Graded #99 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access
  • Multiple administration formats

Where it loses points

  • Limited public information on program details
LillyDirect Foundayo

Graded #173 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard